Commitments and Contingencies (Details) $ in Thousands	12 Months Ended
Dec. 31, 2025 USD ($)
Commitments and Contingencies [Line Items]
Agreement cost	$ 1,330
Service amount	$ 800
LV-100 – Liposomal Nano-Mupirocin [Member]
Commitments and Contingencies [Line Items]
Royalty payment percentage	3.00%
LV-100 – Liposomal Nano-Mupirocin [Member] \| Phase I Clinical Trial [Member]
Commitments and Contingencies [Line Items]
Payment for royalties	$ 150
LV-100 – Liposomal Nano-Mupirocin [Member] \| Phase II Clinical Trial [Member]
Commitments and Contingencies [Line Items]
Payment for royalties	300
LV-100 – Liposomal Nano-Mupirocin [Member] \| Phase III Clinical Trial [Member]
Commitments and Contingencies [Line Items]
Payment for royalties	450
LV-100 – Liposomal Nano-Mupirocin [Member] \| First Commercial Sale [Member]
Commitments and Contingencies [Line Items]
Payment for royalties	$ 600
LV-400 – A Liposomal Platform for Vaccine Development [Member]
Commitments and Contingencies [Line Items]
Royalty payment percentage	3.00%
LV-400 – A Liposomal Platform for Vaccine Development [Member] \| Phase I Clinical Trial [Member]
Commitments and Contingencies [Line Items]
Payment for royalties	$ 150
LV-400 – A Liposomal Platform for Vaccine Development [Member] \| Phase II Clinical Trial [Member]
Commitments and Contingencies [Line Items]
Payment for royalties	300
LV-400 – A Liposomal Platform for Vaccine Development [Member] \| Phase III Clinical Trial [Member]
Commitments and Contingencies [Line Items]
Payment for royalties	450
LV-400 – A Liposomal Platform for Vaccine Development [Member] \| First Commercial Sale [Member]
Commitments and Contingencies [Line Items]
Payment for royalties	$ 600

Percentage of royalties payment of net sales.

No definition available.

Name:	rvrc_PayRoyaltyForNetSales
Namespace Prefix:	rvrc_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

+ Details

Name:	us-gaap_OtherCommitment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of cash outflow for fees classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForFees
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of cash paid for royalties during the current period.

+ References

+ Details

Name:	us-gaap_PaymentsForRoyalties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=rvrc_LV100LiposomalNanoMupirocinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=rvrc_PhaseIClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=rvrc_PhaseIIClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=rvrc_PhaseIIIClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=rvrc_FirstCommercialSaleMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rvrc_LV400ALiposomalPlatformForVaccineDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: